Monopar Therapeutics Operating Expenses Growth & History (MNPR)
Monopar Therapeutics's operating expenses was $16.7M for fiscal 2025.
View full Monopar Therapeutics company overviewMonopar Therapeutics annual operating expenses history
| Fiscal year | Period ended | Operating expenses | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $16.7M | $542,694 | +3.36% |
| 2024 | 2024-12-31 | $16.2M | $7.3M | +83.01% |
| 2023 | 2023-12-31 | $8.8M | −$1.7M | −16.19% |
| 2022 | 2022-12-31 | $10.5M | $1.4M | +15.44% |
| 2021 | 2021-12-31 | $9.1M | $2.6M | +40.23% |
| 2020 | 2020-12-31 | $6.5M | $2.2M | +50.54% |
| 2019 | 2019-12-31 | $4.3M | $992,614 | +29.80% |
| 2018 | 2018-12-31 | $3.3M | −$13.3M | −79.94% |
| 2017 | 2017-12-31 | $16.6M | $15.4M | +1291.91% |
| 2016 | 2016-12-31 | $1.2M | — | — |
Monopar Therapeutics quarterly operating expenses
| Fiscal quarter | Period ended | Operating expenses | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $6.6M | $3.4M | +105.44% |
| Q1 2026 | 2026-03-31 | $5.2M | $2.0M | +62.18% |
| Q4 2025 | 2025-12-31 | $6.2M | −$4.9M | −44.42% |
| Q3 2025 | 2025-09-30 | $4.1M | $2.5M | +159.89% |
| Q2 2025 | 2025-06-30 | $3.2M | $1.4M | +80.81% |
| Q1 2025 | 2025-03-31 | $3.2M | $1.5M | +86.95% |
| Q4 2024 | 2024-12-31 | $11.1M | $9.2M | +479.22% |
| Q3 2024 | 2024-09-30 | $1.6M | −$491,092 | −23.77% |
| Q2 2024 | 2024-06-30 | $1.8M | −$539,425 | −23.17% |
| Q1 2024 | 2024-03-31 | $1.7M | −$801,653 | −31.75% |
| Q4 2023 | 2023-12-31 | $1.9M | −$997,010 | −34.27% |
| Q3 2023 | 2023-09-30 | $2.1M | −$341,351 | −14.18% |
| Q2 2023 | 2023-06-30 | $2.3M | −$435,139 | −15.75% |
| Q1 2023 | 2023-03-31 | $2.5M | $67,858 | +2.76% |
| Q4 2022 | 2022-12-31 | $2.9M | $227,880 | +8.50% |
| Q3 2022 | 2022-09-30 | $2.4M | −$51,675 | −2.10% |
| Q2 2022 | 2022-06-30 | $2.8M | $670,953 | +32.07% |
| Q1 2022 | 2022-03-31 | $2.5M | $562,471 | +29.69% |
| Q4 2021 | 2021-12-31 | $2.7M | $420,368 | +18.59% |
| Q3 2021 | 2021-09-30 | $2.5M | $811,041 | +49.21% |
| Q2 2021 | 2021-06-30 | $2.1M | $628,263 | +42.91% |
| Q1 2021 | 2021-03-31 | $1.9M | $758,701 | +66.79% |
| Q4 2020 | 2020-12-31 | $2.3M | $1.0M | +84.57% |
| Q3 2020 | 2020-09-30 | $1.6M | $888,531 | +117.00% |
| Q2 2020 | 2020-06-30 | $1.5M | $532,023 | +57.08% |
| Q1 2020 | 2020-03-31 | $1.1M | −$271,295 | −19.28% |
| Q4 2019 | 2019-12-31 | $1.2M | $126,072 | +11.47% |
| Q3 2019 | 2019-09-30 | $759,448 | $91,916 | +13.77% |
| Q2 2019 | 2019-06-30 | $932,109 | $264,577 | +39.64% |
| Q1 2019 | 2019-03-31 | $1.4M | $510,049 | +56.85% |
| Q4 2018 | 2018-12-31 | $1.1M | $362,022 | +49.13% |
| Q3 2018 | 2018-09-30 | $667,532 | −$14.2M | −95.52% |
| Q2 2018 | 2018-06-30 | $667,532 | $72,575 | +12.20% |
| Q1 2018 | 2018-03-31 | $897,260 | $523,421 | +140.01% |
| Q4 2017 | 2017-12-31 | $736,801 | — | — |
| Q3 2017 | 2017-09-30 | $14.9M | — | — |
| Q2 2017 | 2017-06-30 | $594,957 | — | — |
| Q1 2017 | 2017-03-31 | $373,839 | — | — |
Monopar Therapeutics operating expenses trends
Over the last five fiscal years, Monopar Therapeutics's operating expenses increased from $6.5M to $16.7M, a change of $10.2M. The latest reported quarter, Q2 2026, shows $6.6M.
What operating expenses mean
Operating expenses are the recurring costs of running a company’s business beyond the direct costs used to calculate gross profit. They commonly include selling, general and administrative expenses, research and development, and other operating costs.
SEC-reported and calculated operating expenses
TickerStat uses operating expenses reported in company SEC filings when available. When a separate total is unavailable, it calculates operating expenses as aligned gross profit minus operating income for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Monopar Therapeutics source filings ↗